Abstract
Introduction
The incidence of patients with type 2 diabetes is increasing worldwide and diabetic kidney disease (DKD) is a major cause of premature disability and death. Interventions in later stage chronic kidney disease (CKD) can only limit the damage and thus it is necessary to risk-stratify incident patients according to their projected disease course (1; 2) . Unfortunately, the prediction of an individual's loss of estimated glomerular filtration rate (eGFR) based on clinical and demographic parameters is poor (3) . Thus, research in the last decade focused on the discovery of molecular markers for the refinement of individual CKD progression (4) .
Several candidate markers have been discovered that showed statistical associations with eGFR decline or progression of proteinuria (5) . However, kidney disease in type 2 diabetic patients is driven by a heterogeneous set of pathophysiological processes (6) . Consequently, it is unlikely that a sole marker can capture all these different pathophysiological processes that lead to CKD progression. Thus investigators focused on parsimonious multi-marker panels. Such a molecular selection was derived and experimentally tested in the EU FP-7 project SysKid (Systems Biology toward Novel Chronic Kidney Disease Diagnosis and Treatment) (7) . The biomarker panel added explained variability to a 'clinical variable only' model but has not yet been thoroughly validated in an independent cohort. In addition, several other prognostic biomarkers for kidney disease progression in patients with diabetes have been identified but were never validated as a combined marker panel in a specifically designed prospective cohort.
The aim of our study was to integrate high evidence biomarker candidates in a parsimonious panel of prognostic markers and to test their ability to predict eGFR loss when combined with commonly available clinical risk factors.
The
BEAt-DKD consortium (Biomarker  Enterprise  to  Attack  DKD; http://www.imi.europa.eu/projects-results/project-factsheets/beat-dkd) was founded to identify targetable mechanisms and pathways underlying initiation and progression of DKD, as well as to identify and validate biomarkers of disease progression and treatment responses. One of its first tasks is the validation of the best available biomarker candidates in a prospective cohort of patients with type 2 diabetes and early stage kidney disease.
Research Design and Methods

Biomarker Selection
Biomarkers for the present study were selected from biomarker candidates generated by the SYSKID and SUMMIT consortia (8; 9) . We integrated diverse sources of information relevant to the relationship with DKD including evidence from literature (4); transcriptomic analyses from microdissected renal tissue ascertained from subjects with DKD (www.nephroseq.org); whole blood methylation profiles from type 1 diabetic patients with and without DKD; and genetic association data. Priority biomarkers from this integration were assessed for availability of Luminex and ELISA assays and combined to maximize the number of markers that could be measured in a single sample aliquot. A listing of candidates from which the current 17 markers were selected is provided in supplement table 1.
Study Cohort and Selection of Study Participants
The study cohort was derived from PROVALID, a prospective multinational cohort study of patients with type 2 diabetes and incident or early CKD (10) (11) (12) 
Outcome of Interest
The outcome of interest was renal function decline over time, which was determined annually by eGFR, estimated according to the CKD-EPI equation (13) .
Clinical Risk Factors
The following baseline clinical risk factors served as candidate predictors: age, gender, serum cholesterol, UACR, HbA1C, MAP and BMI. eGFR at baseline was either part of the dependent variable or included as predictor. Since anemia does not present a problem in early stage CKD, hemoglobin levels were omitted from the models. 
Biomarker Selection and Measurement
Samples Size Estimate
As all 17 biomarkers were pre-selected from previous projects, it was estimated that 500 samples would be sufficient to reach more than 80% power to detect at least a single biomarker with a statistically significant effect on the outcome renal function decline (supplement figure 4). Key assumptions were derived from (7).
Statistical Analysis
Patient characteristics were described by mean and standard deviation, median and Biomarker levels were log2 transformed to normalize their distributions. The model results presented here were pooled by Rubin's rules from multiply imputed datasets to account for uncertainty due to missing data in predictors. Thus, in each model all 481 samples were included. By applying the variable selection procedure to each imputation we obtained selection frequencies facilitating assessment of model instability due to missing data. Our final model comprised predictors chosen in at least half of the imputations. Model instability due to general sampling variation was assessed by drawing bootstrap resamples in each imputed dataset. 13 Complete-case only analyses, the number of available samples per predictor and a description of the multiple imputation procedure is provided in the supplementary material.
Logistic regression models were applied to obtain classification models for progression status based on the predictor values.
P-values less than 0.05 were considered statistically significant and all p-values are two-sided. We used the R statistical software (https://www.r-project.org/foundation, Vienna, AT) for all analyses.
Results
In total, 481 patient baseline plasma samples were measured for 17 biomarkers. A detailed breakdown of availability by marker is provided in supplement table 6. Figure   1 shows biomarker levels grouped by speed of progression of renal function decline.
When comparing median levels using Mann-Whitney U tests, several markers showed a significant difference between the two groups of patients (no adjustment for multiple testing). However, the marker level distributions overlap and the observed differences The weak association with eGFR slopes is further demonstrated by low discriminative power when using logistic regression models to discriminate between stable and fast progressing patients. The resulting low Area Under the Curve (AUC) values corroborate our findings that the biomarkers are mainly associated with mean eGFR baseline levels (supplement table 13 and 14) .
Results from the analysis including baseline eGFR levels as covariate further indicate that the added value of the biomarkers on top of these measurements is low with regards to prediction of future eGFR levels. In corresponding univariable analyses, only six biomarkers remained significantly associated with mean eGFR levels, when baseline eGFR was included in the models (supplement table 15 ). eGFR and to some extent albuminuria were the most important factors for predicting progression but their predictive ability in total was modest.
Niewczas and colleagues showed that, on top of clinical covariates, elevated concentrations of serum TNFR1 in 410 patients with later stage disease and long term FU was strongly associated with baseline GFR and predicted ESRD that happened in 59 patients after a median FU of twelve years (15) . This is in line with our current and previous findings that TNFR1 exhibited the highest explained variability in the longitudinal analysis for eGFR loss. However, death as a competing risk factor in analysis of the progression of kidney disease needs to be considered here. It is possible that differences in lead-time bias between studies explain the discrepancies in biomarker prediction of eGFR decline between the present and other studies (15) . Our previous analysis of nine biomarkers in two cohorts of patients with different baseline eGFR showed that explained variability of eGFR loss in patients with eGFR below 60 mL/min was mainly driven by MMP7 and TNFR1 (7) . In patients with baseline eGFR above 60 mL/min contribution of all markers was modest with an adjusted R 2 of 15% and 35% for a combination of biomarkers and clinical predictors. The inclusion of further eight well investigated biomarkers did not substantially increase the predictability of eGFR loss in our current analysis. However, the fact that nine out of the 17 markers showed statistically significant differences in concentration levels between the group of patients with stable kidney function and the group with fast renal function decline supports the initial marker selection for this study. Yet, our analysis showed that the main contribution of these biomarkers is their association with baseline eGFR values rather than eGFR slopes.
The individual slope of eGFR loss is highly variable in patients with diabetes and may be modified by medication. However, the aim of the present study was to predict the slope from baseline biomarkers independently of subsequent interventions such as comedication, lifestyle changes or any other factors. Therefore, we did not use medication in our main model on purpose, because it would be a baseline-adjustment for interventions that occurred afterwards, hence using information not available at time of prediction. In addition, all patients in the PROVALID study were optimally treated according to guidelines for patients with diabetes (21; 22). An analysis including treatment status at baseline, corroborating the negligible effect of medication on the performance of the biomarkers can be found in supplement tables 20 and 21.
A key strength of PROVALID is that the study was specifically designed for the validation of biomarkers in patients with type 2 diabetes (10). However, our study has a few limitations. The selection of patients from the PROVALID cohort was based on the outcome of eGFR. While this likely leads to over-optimistic results, our rationale was to maximize power to validate the candidate biomarkers utility to predict eGFR loss independently of clinical parameters. Since it turned out that even with the 20 preselection marker performance was poor in this cohort of early stage CKD patients this limitation is irrelevant. A potential limitation is the relative short FU of three years.
However, all patients had baseline and annual eGFR determinations which led to a robust slope estimation and thus stable marker performance estimates.
The strengths of our study are the careful analysis of biomarkers according to EMA and FDA standards in a multinational prospective study (http://academy.gmpcompliance.org/guidemgr/files/UCM368107.PDF). Sample aliquots were stored at minus 80°C immediately after collection and never thawed until analysis. The percentage difference between reruns was well within the FDA recommended range.
A further asset is the thorough statistical analysis in which we dissociated the effects of markers on the prediction of baseline eGFR and slope alone and in combination with clinical covariates known to be key risk factors for CKD progression.
In conclusion, the prediction of eGFR slope using baseline circulating biomarkers in combination with clinical parameters was modest. Most of the predictive power was generated by the association of markers with baseline eGFR, which was by far the strongest predictor of future eGFR levels. Given the inferior performance of this highly selected biomarker set in early stage CKD patients to predict future eGFR loss, it is unlikely that these markers will be useful for clinical decision making. Nevertheless, their assessment might be useful to identify individual biological processes that may contribute to the progression of very early stage renal disease. conduct, and analysis of the study.
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